source
- AstraZeneca says Wainua failure won’t alter M&A plans, stays on track for $80B 2030 goalAstraZeneca said during its Q2 earnings presentation that the late‑stage failure of the antisense therapy Wainua in ATTR‑cardiomyopathy does not derail its goal of reaching $80 billion in revenue b…
- Sarepta appoints Michael Severino as CEO to steer company beyond a turbulent yearSarepta Therapeutics announced that Michael Severino will become its chief executive officer, taking over from longtime leader Doug Ingram. Severino is slated to start on Tuesday and joins the com…